SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91: 16161634.
  • 2
    Dalton JD, Bailey NP, Barrett-Lee PJ, et al. Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy [abstract]. Proc Am Soc Clin Oncol. 1998; 17: 418a.
  • 3
    Cascinu S, Fedeli A, Del Ferro E, Fedeli SL, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol. 1994; 12: 10581062.
  • 4
    Skillings JR, Rogers-Melamed I, Nabholtz J-M, et al. An epidemiological review of red cell transfusions in cancer chemotherapy. Cancer Prev Control. 1999; 3: 207212.
  • 5
    Harrison LB, Shasha D, Shiaova L, White C, Ramdeen B, Portenoy R. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin Oncol. 2001; 28( Suppl 8): 5459.
  • 6
    Sobrero A, Puglisi F, Guglielmi A, et al. Fatigue: a main component of anemia symptomatology. Semin Oncol. 2001; 28( Suppl 8): 1518.
  • 7
    Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000; 5: 353360.
  • 8
    Groopman JE. Fatigue in cancer and HIV/AIDS. Oncology (Huntingt). 1998; 12: 335344.
  • 9
    Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol. 1997( Suppl 2); 34: 412.
  • 10
    Irvine D, Vincent L, Graydon JE, Bubela N, Thompson L. The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. Cancer Nurs. 1994; 17: 367378.
  • 11
    Gullino PM, Grantham FH, Courtney AH. Utilization of oxygen by transplanted tumors in vivo. Cancer Res. 1967; 27: 10201030.
  • 12
    Bush RS. The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys. 1986; 12: 20472050.
  • 13
    Girinski T, Pejovic-Lenfant MH, Bourhis J, et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys. 1989; 16: 3742.
  • 14
    Fein DA, Lee WR, Hanlon AL, et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol. 1995; 13: 20772083.
  • 15
    Takigawa N, Segawa Y, Okahara M, et al. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer. 1996; 15: 6777.
  • 16
    Constantinou EC, Daly W, Fung CY, Willett CG, Kaufman DS, DeLaney TF. Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys. 1997; 39: 651657.
  • 17
    Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 1998; 48: 149156.
  • 18
    Teicher BA. Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. Hematol Oncol Clin North Am. 1995; 9: 475506.
  • 19
    Logsdon MD, Eifel PJ. FIGO IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavity radiation therapy. Int J Radiat Oncol Biol Phys. 1999; 43: 763775.
  • 20
    Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999; 86: 15281536.
  • 21
    Hong JH, Tsai CS, Chang JT, et al. The prognostic significance of pre- and post-treatment with SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys. 1998; 41: 823830.
  • 22
    Lee WR, Berkey B, Marcial V, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys. 1998; 42; 10691075.
  • 23
    Warde P, O'Sullivan B, Bristow RG, et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys. 1998; 41: 347353.
  • 24
    Cole CJ, Pollack A, Zagars GK, et al. Local control of muscle invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys. 1995; 32: 331340.
  • 25
    Dunphy EP, Petersen IA, Cox RS, et al. The influence of initial hemoglobin and blood pressure on results of radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1989; 16: 11731178.
  • 26
    Henry DH. Changing patterns of care in the management of anemia. Semin Oncol. 1992; 19( Suppl 8): 37.
  • 27
    Henke M, Guttenberger R, Barke A, Pajonk F, Pötter R, Frommhold H. Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol. 1999; 50: 185190.
  • 28
    Sweeney PJ, Nicolae D, Ignacio L, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. Br J Cancer. 1998; 77: 19962002.
  • 29
    Dusenbery KE, McGuire WA, Holt PJ, et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 1994; 29: 10791084.
  • 30
    Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys. 1993; 27: 11471152.
  • 31
    Demetri GD, Kris M, Wade J, Degos L, Cella D, for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol. 1998; 16: 34123425.
  • 32
    Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S, for the Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997; 15: 12181234.
  • 33
    Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001; 19: 28752882.
  • 34
    Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002; 95: 888895.
  • 35
    Littlewood TJ, Bajetta E, Nortier JWR, et al, for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001; 19: 28652874.